Pulse Biosciences slips despite Q4 beat after deal to sell shares
Pulse Biosciences (PLSE) shares fell on Friday despite exceeding Q4 2025 financial forecasts. The decline followed the announcement of an agreement with TD Securities to sell up to ~$60M worth of shares. The equity distribution agreement allows Pulse to offer approximately ~$59.98M shares of its common stock over time.
Source: businessinsider The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments